{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:07:04Z","timestamp":1764022024063,"version":"3.45.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02911-1","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:44:50Z","timestamp":1762353890000},"page":"2523-2531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lung immune prognostic index as a biomarker for predicting the benefit of immune checkpoint inhibitor plus chemotherapy in older patients with non-small cell lung cancer: a secondary analysis of the NEJ057 study"],"prefix":"10.1007","volume":"30","author":[{"given":"Takehiro","family":"Tozuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Tsukita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Kushiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayo","family":"Soda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Hamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Namba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Makiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7126-3153","authenticated-orcid":false,"given":"Hajime","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2911_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/JCO.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei H, Gettinger S, Vokes EE et al (2021) Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 39:723\u2013733. https:\/\/doi.org\/10.1200\/JCO.20.01605","journal-title":"J Clin Oncol"},{"key":"2911_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"2911_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-6","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819\u20131830. https:\/\/doi.org\/10.1016\/S0140-6736(18)32409-6","journal-title":"Lancet"},{"key":"2911_CR4","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1801005","journal-title":"N Engl J Med"},{"key":"2911_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040\u20132051. https:\/\/doi.org\/10.1056\/NEJMoa1810865","journal-title":"N Engl J Med"},{"key":"2911_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West H, McCleod M, Hussein M et al (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6","journal-title":"Lancet Oncol"},{"key":"2911_CR7","doi-asserted-by":"publisher","first-page":"9001","DOI":"10.1200\/JCO.2021.39.15_suppl.9001","volume":"39","author":"O Akinboro","year":"2021","unstructured":"Akinboro O, Vallejo JJ, Mishra-Kalyani PS et al (2021) Outcomes of anti\u2013PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non\u2013small cell lung cancer (NSCLC) with PD-L1 score 1\u201349%: FDA pooled analysis. J Clin Oncol 39:9001\u20139001. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.9001","journal-title":"J Clin Oncol"},{"key":"2911_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaoncol.2023.6277","volume":"10","author":"Y Tsukita","year":"2024","unstructured":"Tsukita Y, Tozuka T, Kushiro K et al (2024) Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer. JAMA Oncol 10:439\u2013447. https:\/\/doi.org\/10.1001\/jamaoncol.2023.6277","journal-title":"JAMA Oncol"},{"key":"2911_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.cllc.2025.01.014","volume":"26","author":"APC Barrichello","year":"2025","unstructured":"Barrichello APC, Elkrief A, Ricciuti B et al (2025) Tumor immunophenotypic correlates in patients aged 80 years or older with non-small cell lung cancer and outcomes to first-line Pembrolizumab in PD-L1 high (\u226550%) patients. Clin Lung Cancer 26:288-298.e8. https:\/\/doi.org\/10.1016\/j.cllc.2025.01.014","journal-title":"Clin Lung Cancer"},{"key":"2911_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109946","volume":"27","author":"J Gao","year":"2024","unstructured":"Gao J, Zhang P, Nie X et al (2024) Proteomic and metabolomic profiling of plasma predicts immune-related adverse events in older patients with advanced non-small cell lung cancer. iScience 27:109946. https:\/\/doi.org\/10.1016\/j.isci.2024.109946","journal-title":"iScience"},{"key":"2911_CR11","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.21873\/anticanres.13744","volume":"39","author":"T Hasegawa","year":"2019","unstructured":"Hasegawa T, Yanagitani N, Utsumi H et al (2019) Association of high neutrophil-to-lymphocyte ratio with poor outcomes of pembrolizumab therapy in high-PD-L1-expressing non-small cell lung cancer. Anticancer Res 39:6851\u20136857. https:\/\/doi.org\/10.21873\/anticanres.13744","journal-title":"Anticancer Res"},{"key":"2911_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.lungcan.2019.09.009","volume":"136","author":"F Shoji","year":"2019","unstructured":"Shoji F, Takeoka H, Kozuma Y et al (2019) Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer 136:45\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2019.09.009","journal-title":"Lung Cancer"},{"key":"2911_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1186\/s12885-021-08194-9","volume":"21","author":"KL Ayers","year":"2021","unstructured":"Ayers KL, Ma M, Debussche G et al (2021) A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer 21:441. https:\/\/doi.org\/10.1186\/s12885-021-08194-9","journal-title":"BMC Cancer"},{"key":"2911_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.resinv.2022.10.003","volume":"61","author":"T Tanaka","year":"2023","unstructured":"Tanaka T, Yoshida T, Masuda K et al (2023) Prognostic role of modified Glasgow prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. Respir Investig 61:74\u201381. https:\/\/doi.org\/10.1016\/j.resinv.2022.10.003","journal-title":"Respir Investig"},{"key":"2911_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","volume":"4","author":"L Mezquita","year":"2018","unstructured":"Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4:351\u2013357. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4771","journal-title":"JAMA Oncol"},{"key":"2911_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2911_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1186\/s12885-024-12271-0","volume":"24","author":"Y Guo","year":"2024","unstructured":"Guo Y, Pan Y, Wan J et al (2024) Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review. BMC Cancer 24:523. https:\/\/doi.org\/10.1186\/s12885-024-12271-0","journal-title":"BMC Cancer"},{"key":"2911_CR18","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162\u2013174. https:\/\/doi.org\/10.1038\/nri2506","journal-title":"Nat Rev Immunol"},{"key":"2911_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S et al (2021) IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 359:104254. https:\/\/doi.org\/10.1016\/j.cellimm.2020.104254","journal-title":"Cell Immunol"},{"key":"2911_CR20","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1100","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942\u2013949. https:\/\/doi.org\/10.1038\/nm1100","journal-title":"Nat Med"},{"key":"2911_CR21","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1158\/1078-0432.CCR-08-0037","volume":"14","author":"CW Tseng","year":"2008","unstructured":"Tseng CW, Hung CF, Alvarez RD et al (2008) Pretreatment with cisplatin enhances E7-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 14:3185\u20133192. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0037","journal-title":"Clin Cancer Res"},{"key":"2911_CR22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clim.2008.06.006","volume":"129","author":"L Zhang","year":"2008","unstructured":"Zhang L, Dermawan K, Jin M et al (2008) Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 129:219\u2013229. https:\/\/doi.org\/10.1016\/j.clim.2008.06.006","journal-title":"Clin Immunol"},{"key":"2911_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22074","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ et al (2017) T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545:60\u201365. https:\/\/doi.org\/10.1038\/nature22074","journal-title":"Nature"},{"key":"2911_CR24","doi-asserted-by":"publisher","first-page":"4960","DOI":"10.1158\/1078-0432.CCR-17-2386","volume":"24","author":"RW Joseph","year":"2018","unstructured":"Joseph RW, Elassaiss-Schaap J, Kefford R et al (2018) Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res 24:4960\u20134967. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2386","journal-title":"Clin Cancer Res"},{"key":"2911_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108039","volume":"199","author":"E Auclin","year":"2025","unstructured":"Auclin E, Roulleaux Dugage M, Gorria T et al (2025) Validation of the lung immune prognostic index in patients with untreated advanced non-small cell lung cancer: post hoc analysis of the IMpower 130, 131 and 150 trials. Lung Cancer 199:108039. https:\/\/doi.org\/10.1016\/j.lungcan.2024.108039","journal-title":"Lung Cancer"},{"key":"2911_CR26","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaoncol.2019.1747","volume":"5","author":"D Kazandjian","year":"2019","unstructured":"Kazandjian D, Gong Y, Keegan P et al (2019) Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol 5:1481\u20131485. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1747","journal-title":"JAMA Oncol"},{"key":"2911_CR27","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jtho.2019.05.004","volume":"14","author":"MJ Sorich","year":"2019","unstructured":"Sorich MJ, Rowland A, Karapetis CS et al (2019) Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials. J Thorac Oncol 14:1440\u20131446. https:\/\/doi.org\/10.1016\/j.jtho.2019.05.004","journal-title":"J Thorac Oncol"},{"key":"2911_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cllc.2023.11.007","volume":"25","author":"M Riudavets","year":"2024","unstructured":"Riudavets M, Auclin E, Mosteiro M et al (2024) Association between lung immune prognostic index and durvalumab consolidation outcomes in patients with locally advanced non-small-cell lung cancer. Clin Lung Cancer 25:233-243.e8. https:\/\/doi.org\/10.1016\/j.cllc.2023.11.007","journal-title":"Clin Lung Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02911-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02911-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:42Z","timestamp":1764021762000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02911-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2911"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02911-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"3 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TT reported receiving personal fees from AstraZeneca K.K. and Chugai Pharmaceutical Co., Ltd. outside the submitted work. YT reported receiving personal fees from AstraZeneca K.K., Chugai Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan K.K., Bristol-Meyers Squibb, MSD K.K., Nippon Boehringer Ingelheim, and Eisai outside the submitted work. KK reported receiving personal fees from Chugai Pharmaceutical, Merck Biopharma, Takeda Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan K.K., Kyowa Kirin, and Teijin Healthcare outside the submitted work. SH reported receiving personal fees from AstraZeneca K.K. and Chugai Pharmaceutical outside the submitted work. KH reported receiving personal fees from AstraZeneca K.K. outside the submitted work. T reported receiving personal fees from Ono Pharmaceutical, Merck Sharp & Dohme K.K., and Chugai Pharmaceutical outside the submitted work. SM reported receiving honoraria from AstraZeneca K.K., Bristol-Myers Squibb Company, Chugai Pharmaceutical, Eli Lilly Japan K.K., MSD K.K., and Ono Pharmaceutical outside the submitted work. MS reported receiving grants from Taiho Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan K.K., Nippon Kayaku, and Kyowa Kirin and personal fees from AstraZeneca K.K., MSD K.K., Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan K.K., Ono Pharmaceutical, Bristol-Myers Squibb Company, Nippon Boehringer Ingelheim, Pfizer Japan Inc., Novartis Pharma K.K., Takeda Pharmaceutical, Kyowa Kirin, Nippon Kayaku, Daiichi Sankyo, Merck Biopharma, and Amgen Inc. outside the submitted work. KK reported receiving personal fees from AstraZeneca K.K. and Janssen Pharmaceutical K.K. and research funding from Zeria Pharmaceutical outside the submitted work. He is also listed as a co-inventor on Japanese patent #7422498, titled \u201cPeptide inhibiting cell migration, cell invasion, and cancer metastasis.\u201d HA reported receiving both grants as well as personal fees from AstraZeneca K.K. and personal fees from AstraZeneca K.K., Chugai Pharmaceutical, Ono Pharmaceutical, MSD K.K., Eli Lilly, Kyowa Hakko Kirin, Merck, and Taiho Pharmaceutical outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Institutional Review Boards of Tohoku University Hospital. Informed consent from individuals for the use of their medical data was obtained by the opt-out method based on a disclosure document.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}